223 related articles for article (PubMed ID: 26141946)
1. Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers.
Li C; Huang S; Armstrong EA; Francis DM; Werner LR; Sliwkowski MX; van der Kogel A; Harari PM
Mol Cancer Ther; 2015 Sep; 14(9):2049-59. PubMed ID: 26141946
[TBL] [Abstract][Full Text] [Related]
2. Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.
De Pauw I; Wouters A; Van den Bossche J; Deschoolmeester V; Baysal H; Pauwels P; Peeters M; Vermorken JB; Lardon F
Cancer Biother Radiopharm; 2017 Sep; 32(7):229-238. PubMed ID: 28910149
[TBL] [Abstract][Full Text] [Related]
3. Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models.
Francis DM; Huang S; Armstrong EA; Werner LR; Hullett C; Li C; Morris ZS; Swick AD; Kragh M; Lantto J; Kimple RJ; Harari PM
Clin Cancer Res; 2016 Feb; 22(3):633-43. PubMed ID: 26420857
[TBL] [Abstract][Full Text] [Related]
4. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.
Huang S; Li C; Armstrong EA; Peet CR; Saker J; Amler LC; Sliwkowski MX; Harari PM
Cancer Res; 2013 Jan; 73(2):824-33. PubMed ID: 23172311
[TBL] [Abstract][Full Text] [Related]
5. Higher Anti-Tumor Efficacy of the Dual HER3-EGFR Antibody MEHD7945a Combined with Ionizing Irradiation in Cervical Cancer Cells.
Bourillon L; Demontoy S; Lenglet A; Zampieri A; Fraisse J; Jarlier M; Boissière-Michot F; Perrochia H; Rathat G; Garambois V; Bonnefoy N; Michaud HA; Chardès T; Tosi D; Pèlegrin A; Azria D; Larbouret C; Bourgier C
Int J Radiat Oncol Biol Phys; 2020 Apr; 106(5):1039-1051. PubMed ID: 31959545
[TBL] [Abstract][Full Text] [Related]
6. Sym004, a novel anti-EGFR antibody mixture, augments radiation response in human lung and head and neck cancers.
Huang S; Peet CR; Saker J; Li C; Armstrong EA; Kragh M; Pedersen MW; Harari PM
Mol Cancer Ther; 2013 Dec; 12(12):2772-81. PubMed ID: 24130052
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
[TBL] [Abstract][Full Text] [Related]
8. Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.
Juric D; Dienstmann R; Cervantes A; Hidalgo M; Messersmith W; Blumenschein GR; Tabernero J; Roda D; Calles A; Jimeno A; Wang X; Bohórquez SS; Leddy C; Littman C; Kapp AV; Shames DS; Penuel E; Amler LC; Pirzkall A; Baselga J
Clin Cancer Res; 2015 Jun; 21(11):2462-70. PubMed ID: 26034219
[TBL] [Abstract][Full Text] [Related]
9. Imaging EGFR and HER3 through
McKnight BN; Kuda-Wedagedara ANW; Sevak KK; Abdel-Atti D; Wiesend WN; Ku A; Selvakumar D; Carlin SD; Lewis JS; Viola-Villegas NT
Sci Rep; 2018 Jun; 8(1):9043. PubMed ID: 29899472
[TBL] [Abstract][Full Text] [Related]
10. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.
Tao JJ; Castel P; Radosevic-Robin N; Elkabets M; Auricchio N; Aceto N; Weitsman G; Barber P; Vojnovic B; Ellis H; Morse N; Viola-Villegas NT; Bosch A; Juric D; Hazra S; Singh S; Kim P; Bergamaschi A; Maheswaran S; Ng T; Penault-Llorca F; Lewis JS; Carey LA; Perou CM; Baselga J; Scaltriti M
Sci Signal; 2014 Mar; 7(318):ra29. PubMed ID: 24667376
[TBL] [Abstract][Full Text] [Related]
11. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
[TBL] [Abstract][Full Text] [Related]
12. Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma.
Jiang N; Wang D; Hu Z; Shin HJ; Qian G; Rahman MA; Zhang H; Amin AR; Nannapaneni S; Wang X; Chen Z; Garcia G; MacBeath G; Shin DM; Khuri FR; Ma J; Chen ZG; Saba NF
Mol Cancer Ther; 2014 Jul; 13(7):1826-36. PubMed ID: 24748655
[TBL] [Abstract][Full Text] [Related]
13. Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma.
Li C; Brand TM; Iida M; Huang S; Armstrong EA; van der Kogel A; Wheeler DL
Discov Med; 2013 Sep; 16(87):79-92. PubMed ID: 23998444
[TBL] [Abstract][Full Text] [Related]
14. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
Iida M; Brand TM; Starr MM; Huppert EJ; Luthar N; Bahrar H; Coan JP; Pearson HE; Salgia R; Wheeler DL
Mol Cancer; 2014 Oct; 13():242. PubMed ID: 25344208
[TBL] [Abstract][Full Text] [Related]
15. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose.
Kamath AV; Lu D; Gupta P; Jin D; Xiang H; Wong A; Leddy C; Crocker L; Schaefer G; Sliwkowski MX; Damico-Beyer LA
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1063-9. PubMed ID: 22203367
[TBL] [Abstract][Full Text] [Related]
16. ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models.
Zhang L; Castanaro C; Luan B; Yang K; Fan L; Fairhurst JL; Rafique A; Potocky TB; Shan J; Delfino FJ; Shi E; Huang T; Martin JH; Chen G; Macdonald D; Rudge JS; Thurston G; Daly C
Mol Cancer Ther; 2014 May; 13(5):1345-55. PubMed ID: 24634416
[TBL] [Abstract][Full Text] [Related]
17. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
[TBL] [Abstract][Full Text] [Related]
18. A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.
Xiao Z; Carrasco RA; Schifferli K; Kinneer K; Tammali R; Chen H; Rothstein R; Wetzel L; Yang C; Chowdhury P; Tsui P; Steiner P; Jallal B; Herbst R; Hollingsworth RE; Tice DA
Mol Cancer Ther; 2016 Apr; 15(4):689-701. PubMed ID: 26880266
[TBL] [Abstract][Full Text] [Related]
19. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation.
Harari PM; Huang SM
Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):427-33. PubMed ID: 11173137
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models.
Wu Y; Zhang Y; Wang M; Li Q; Qu Z; Shi V; Kraft P; Kim S; Gao Y; Pak J; Youngster S; Horak ID; Greenberger LM
Mol Cancer Ther; 2013 Apr; 12(4):427-37. PubMed ID: 23395887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
